ST LOUIS BREAST TISSUE REGISTRY

乳腺癌病理检查的目的之一 组织是用来预测疾病的未来进程， 有效的治疗方式 在许多情况下， 过于笼统，最好的治疗方法尚不清楚。发展新 肿瘤标记物和对现有标记物的彻底检测提供了真实的希望 用于确定可靠的预后指标;然而， 由于缺乏来自患者的足够的肿瘤组织供应而受阻 已知的结果。乳腺肿瘤组织存档的可用性 石蜡块，结合患者的随访数据， 肿瘤标志物研究的重要临床资源。的目的 这个项目就是要提供这样一种资源。我们建议设立 圣路易斯乳腺组织登记处，将提供未染色的石蜡 切片，从明确定义的乳腺癌子集，以研究者 他们计划研究各种肿瘤标志物的预后意义。 注册处将由一间私人执业律师事务所及七间私人执业律师事务所组成 医院为基础的团体谁同意集中他们的资源， 石蜡包埋乳腺肿瘤标本的登记， 存在重要的后续信息。病理学家在 合作机构将提供石蜡块， 各肿瘤登记中心将提供随访数据。我们期望 收集并处理至少8000份，以分发给研究者 乳腺癌组织样本肿瘤标本共507例 （估计）导管原位癌，和2，535例（估计） 淋巴结阴性乳腺癌所有与肿瘤有关的信息 样本和患者随访将输入计算机化的 中央数据库（使用Gemstone/Geode面向对象的数据库 管理系统）位于华盛顿大学 药圣路易斯乳腺组织登记处将与类似的 在美国和美国国立卫生研究院的登记处， 形成具有统一政策和业务的登记处联盟。 我们希望从这些样本中收集的肿瘤标志物数据 病例将大大提高我们预测结果的能力， 从而改善乳腺癌患者的治疗。

One of the objectives of the pathologic examination of breast carcinoma tissue is to predict the future course of the disease and even to predict the form of therapy that will be effective. For many cases the prognosis is too general and the best therapy is unknown. The development of new tumor markers and the thorough testing of existing ones offer real promise for identifying reliable prognostic indicators; however, progress has been hindered by the lack of an adequate supply of tumor tissue from patients with known outcome. The availability of archived breast tumor tissue in paraffin blocks, combined with follow-up data on patients, would provide a significant clinical resource for tumor marker studies. The purpose of this project is to provide such a resource. We propose to establish the St.Louis Breast Tissue Registry, which will provide unstained paraffin sections, from well-defined subsets of breast carcinoma, to investigators who plan to study the prognostic significance of various tumor markers. The Registry will consist of a consortium of 1 private practice and 7 hospital-based groups who have agreed to pool their resources and create a registry of paraffin-embedded breast tumor specimens for which significant follow-up information exists. Pathologists at the collaborating institutions will supply the paraffin blocks, and their respective tumor registries will supply the follow-up data. We expect to collect and process for distribution to investigators a minimum of 8000 samples of breast cancer tissue. The tumor samples include 507 cases (estimated) of ductal carcinoma in-situ, and 2,535 cases (estimated) of node-negative breast carcinoma. All the information relating to the tumor specimens and patient follow-up will be entered into a computerized central database (using the Gemstone/Geode object-oriented database management system) located at the Washington University School of Medicine. The St. Louis Breast Tissue Registry will cooperate with similar registries in the United States and with the National Institutes of Health to form a consortium of registries with uniform policies and operations. We expect that the tumor marker data collected on specimens from these cases will significantly advance our ability to predict outcome and will lead to improved therapy for patients with breast cancer.